2021 is off to a Fast Start for Gastroenterology
Gastroenterology deals have been accelerating, with eight closed transactions in Q4 2020 and another eight already closed (as of Jan 19) in 2021. We believe this will be a very big year for GI.
Private Equity Moving Outside Surgical Specialties
In many ways, the third wave of private equity investment in physician-owned businesses is starting to mature. We view this third wave as having started around 2015 with investments in ophthalmology and dermatology practices. Earlier investments in radiology and emergency medicine, or pure-play ASCs, are really part of an earlier wave.
White Paper: Private Equity Investment in Physician Owned Specialty Practices
The FOCUS healthcare team represents medical practices and ancillary businesses in specialties where private equity-backed consolidation is occurring. We track activity in key verticals and maintain strong relationships with private equity firms and their portfolio companies.
FOCUS Healthcare Team Members Close 8 Medical Practice Transactions in 18 Months
Members of the FOCUS Healthcare team announced eight completed transactions for a combined 15 clinical businesses in the last 18 months.
FOCUS Investment Banking Represents Clinart in its Acquisition by Greater Cincinnati-based CTI Clinical Trial and Consulting Services
FOCUS Investment Banking (“FOCUS”), a Washington DC-based investment bank, represented Clinart, a regional CRO (Contract Research Organization) located in Dubai, in its acquisition by CTI, Clinical Trial and Consulting Services, an international CRO headquartered in Cincinnati, Ohio.
White Paper: Private Equity Investment in Ophthalmology – August 2020 State of the Market
A comprehensive view of ophthalmology's recovery from the pandemic shutdown. We review changes in elective surgery, the emerging investor interest in retina practices, private equity acquisition activity, geographic development, and changes to acquisition practice size. As the COVID-19 fog begins to clear, we see significant near-term promise and a potential return to record deal levels.
White Paper: Private Equity Investment in Dermatology – April 2020 State of the Market
After seven strong years, private equity investment in dermatology has been in decline since 2019. Now, elective procedure bans and shelter-in-place orders have practice owners wondering if the opportunity to sell has passed. This paper examines the differing views on pe-backed consolidation, key performance indicators, investor activity, and saturation by geography and practice size. We see several positive factors for our current and potential clients within a coming private equity player restructuring.
Private Equity and Dermatology: Acquisition Locations and Concentration
Eight years of consolidation activity has resulted in a wide spread of PE-backed practices across the United States.
Dermatology and Private Equity: Significant Potential Remains
Based on our detailed tracking and analysis, the dermatology market is only 11.5% consolidated as of this publication.
Gastroenterology Acquisitions Spread Across America
Two key factors provide a view of current and future consolidation speed.
